Vishnu Chemicals FY26: ₹1,610 Cr Revenue, Operating at Capacity—But the Multiple Sits Flat While Margins Rest

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Vishnu Chemicals hit ₹1,610 crore revenue in FY26, up 11.3% year-on-year, delivering its highest-ever PAT of ₹142 crore. The company trades at 27.9x earnings—a tick cheaper than the median peer at 28.4x—yet the multiple has not budged for three years while ROCE sits at 16.3%, well below the 20% threshold that would make capital compounding obvious.

Revenue growth stumbled (5% over three years), but the company is now managing three major strategic bets: a chrome ore mine in South Africa (backward integration, phased ops from Q1 FY27), a strontium carbonate plant (import substitute, customer approvals pending Q4), and a ₹320 crore capex for DMSO and chrome oxide green (both due FY27–FY28). Each has potential; none have materialized.

The balance sheet carries ₹527 crore borrowing against a market cap of ₹3,965 crore, and cash flow from operations reached ₹127 crore in FY26. Inventory, however, ballooned to ₹513 crore—a warning flag in a working-capital business—and the operating cycle has stretched to 148 days, eating cash velocity.

The question: Is this a business hitting its stride at last, or one loaded with execution risk and high debt financing a portfolio of optionality?

2. Introduction

Vishnu Chemicals was incorporated in 1989 and has spent 35+ years refining the art of making specialty chemicals—chromium compounds, barium products—that others need but few can make at scale and cost. The company operates six units across three states: Telangana (chromium), Andhra Pradesh (barium, through Vishnu Barium Private Limited), and Chhattisgarh. It exports to 50+ countries, supplies 15+ industries, and in FY25 posted its first full-year dividend increase in years.

The last two years have been a sprint toward integration. In FY24, Vishnu acquired Ramadas Minerals (barytes beneficiation); in FY25, it picked up Jayansree Pharma for ₹52 crore and renamed it Vishnu Strontium. In late 2024, it signed a definitive agreement for a chrome ore mine in South Africa—₹58 crore, expected to kick off by Q1 FY27. Each move signals the same message: lock in raw material costs, escape commodity pricing, improve margins.

But strategy and execution are different animals. FY26 saw PAT grow 12.3% while revenue grew 11.3%, a modest spread. EBITDA margin landed at 15.7%, down from 15.8% the year before. And in May 2026, the independent director board announced plans for a ₹320 crore capex to build DMSO and chrome oxide green plants, funded with ₹240 crore of new debt and ₹80 crore of internal cash.

3. Business Model: WTF Do They Even Do?

Vishnu Chemicals makes specialty inorganic chemicals. The core: chromium compounds (sodium dichromate, basic chromium sulphate, potassium dichromate, chromic acid, chrome oxide green, white sodium sulphate). These flow into tanning, electroplating, pigments, dyes, pharmaceuticals, refractory, and timber treatment.

The secondary pillar: barium compounds, manufactured by Vishnu Barium Private Limited—barium carbonate, precipitated barium sulphate, sodium sulphide. Applications: ceramics, paints, water treatment, glass, plastic, paper, battery technology.

The new frontier: strontium carbonate, launched via Vishnu Strontium (acquired FY25, commercialized Q2 FY26). Target markets: glass, ceramics, EV batteries, magnets, medical devices. Management calls it a complete import substitute; China doesn’t export strontium aggressively, and India imports ~4,000 TPA annually. Vishnu has installed 10,000 TPA capacity, expandable to 17,000.

Revenue mix FY26: domestic ₹834 crore (52%), exports ₹783 crore (48%)—a deliberate rebalance away from the prior year’s 54% domestic, 46% export split. This is intentional, not accidental; the company has said it is managing toward 50:50 balance across both stable cash and volatility-hedging exposure.

The old manufacturing playbook: buy raw materials, add labor and energy, sell at market prices. Margins compress when ore prices spike.

The new playbook: own the ore (chrome, barytes), own the value-add (strontium, DMSO, chrome oxide), own the distribution (global footprint, regional teams). It’s a margin story disguised as a capex cycle.

4. Financials Overview

Figures are consolidated, in ₹ crore. Result type: Yearly. Basis: Consolidated.

Revenue accelerated modestly. EBITDA margin held at 15.7% (vs 15.8% prior year), neither expanding nor collapsing. PAT growth slightly outpaced revenue growth, a sign of operational discipline even as gross margins stayed around 45%.

From the February 2026 concall, Q3 FY26 saw revenue of ₹411 crore and gross margin of 44.8%, with EBITDA margin at 15.0%—a quarter of steady-state execution. Management flagged the global macro as “soft,” tariff uncertainty on US exports (53% duty on chrome chemicals, now “coming down”), and elevated chrome ore prices as headwinds. Domestic demand was described as “quite resilient,” with gains in electroplating, wood preservative, and pigment verticals.

The strontium plant (Vishnu Strontium) is operating at 20–25% utilization while customer approvals progress. Management targets 80% utilization by Q1 FY27, with “regular sales” expected to ramp then. At 80%, gross margin targets are pegged at 50–52% in this product—twice the consolidated average—implying real upside if approvals convert.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market pays 27.9x earnings here versus a peer median of 28.4x—nearly parity, a rarity in specialty chemicals where larger players like Pidilite trade at 63.5x and smaller, challenged ones like Aarti at 38.8x. The 5-year P/E average of 23.6x sits below current levels, suggesting the stock has repriced upward.

ROE at 14.3% is below the 5-year average of 19.8%, and well below the return target that makes sustained equity reinvestment